+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 50Years +
All Genders
ID07053358

Evaluating the Safety and Effectiveness of LX111 Gene Therapy Injection for Neovascular Age-related Macular Degeneration in Adults 50 and Older

Led by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2026-03-10

10

Participants Needed

1

Research Sites

161 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of LX111 gene therapy for patients with neovascular age-related macular degeneration nAMD, a condition affecting the eyes. This early phase 1 study focuses on adults aged 50 and older who have active choroidal neovascularization CNV related to nAMD and have shown some response to prior anti-VEGF treatments. Participants will receive a single injection of LX111 directly into one eye on Day 0. The study monitors participants for dose-limiting toxicity during the first 4 weeks and tracks adverse events in the eyes and body for up to 52 weeks after treatment. Researchers will also assess changes in vision and retinal thickness at several points within the year and note whether additional anti-VEGF injections are needed. During the study, participants will attend follow-up visits for eye exams, vision tests, and imaging to measure treatment effects and safety. Researchers will closely observe any side effects and collect data on vision changes over time. The total participation lasts about one year, allowing detailed monitoring of the gene therapys impact and safety.

CONDITIONS

Brief Title

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here